Albert DH - Search Results

1

5-lipoxygenase inhibitory activity of zileuton.

Carter GW, Young PR, Albert DH, Bouska J, Dyer R, Bell RL, Summers JB, Brooks DW. Carter GW, et al. Among authors: albert dh. J Pharmacol Exp Ther. 1991 Mar;256(3):929-37. J Pharmacol Exp Ther. 1991. PMID: 1848634

2

The discovery and development of zileuton: an orally active 5-lipoxygenase inhibitor.

Bell RL, Young PR, Albert D, Lanni C, Summers JB, Brooks DW, Rubin P, Carter GW. Bell RL, et al. Int J Immunopharmacol. 1992 Apr;14(3):505-10. doi: 10.1016/0192-0561(92)90182-k. Int J Immunopharmacol. 1992. PMID: 1618602 Review.

3

Pharmacokinetics, safety, and ability to diminish leukotriene synthesis by zileuton, an inhibitor of 5-lipoxygenase.

Rubin P, Dubé L, Braeckman R, Swanson L, Hansen R, Albert D, Carter G. Rubin P, et al. Agents Actions Suppl. 1991;35:103-16. Agents Actions Suppl. 1991. PMID: 1781415 Clinical Trial.

4

Properties of ABT-299, a prodrug of A-85783, a highly potent platelet activating factor receptor antagonist.

Albert DH, Conway RG, Magoc TJ, Tapang P, Rhein DA, Luo G, Holms JH, Davidsen SK, Summers JB, Carter GW. Albert DH, et al. J Pharmacol Exp Ther. 1996 Jun;277(3):1595-606. J Pharmacol Exp Ther. 1996. PMID: 8667228

5

The role of platelet-activating factor (PAF) and the efficacy of ABT-491, a highly potent and selective PAF antagonist, in experimental allergic rhinitis.

Albert DH, Malo PE, Tapang P, Shaughnessy TK, Morgan DW, Wegner CD, Curtin ML, Sheppard GS, Xu L, Davidsen SK, Summers JB, Carter GW. Albert DH, et al. J Pharmacol Exp Ther. 1998 Jan;284(1):83-8. J Pharmacol Exp Ther. 1998. PMID: 9435164

6

Synthesis and structure-activity relationships of a series of novel benzopyran-containing platelet activating factor antagonists.

Guinn DE, Summers JB, Heyman HR, Conway RG, Rhein DA, Albert DH, Magoc T, Carter GW. Guinn DE, et al. Among authors: albert dh. J Med Chem. 1992 May 29;35(11):2055-61. doi: 10.1021/jm00089a016. J Med Chem. 1992. PMID: 1317924

7

Platelet activating factor antagonists.

Summers JB, Albert DH. Summers JB, et al. Among authors: albert dh. Adv Pharmacol. 1995;32:67-168. doi: 10.1016/s1054-3589(08)61012-1. Adv Pharmacol. 1995. PMID: 7748804 Review. No abstract available.

8

Ex vivo inhibition of PAF-induced beta-thromboglobulin release in man by ABT-299, a potent PAF antagonist.

Albert DH, Magoc TJ, Kleinert HD, Sun E, Reyes AE, Carter GW, Summers JB. Albert DH, et al. Adv Exp Med Biol. 1996;416:381-7. doi: 10.1007/978-1-4899-0179-8_61. Adv Exp Med Biol. 1996. PMID: 9131177 Clinical Trial. No abstract available.

9

Pharmacology of ABT-491, a highly potent platelet-activating factor receptor antagonist.

Albert DH, Magoc TJ, Tapang P, Luo G, Morgan DW, Curtin M, Sheppard GS, Xu L, Heyman HR, Davidsen SK, Summers JB, Carter GW. Albert DH, et al. Eur J Pharmacol. 1997 Apr 23;325(1):69-80. doi: 10.1016/s0014-2999(97)00109-x. Eur J Pharmacol. 1997. PMID: 9151941

10

Ex vivo inhibition of beta-thromboglobulin release following administration to man of ABT-299, a novel prodrug of a potent platelet activating factor antagonist.

Albert DH, Magoc TJ, Menacherry SD, Morgan DW, Sun E, Reyes AE, Kleinert HD, Carter GW, Summers JB. Albert DH, et al. Inflamm Res. 1997 Jul;46(7):272-7. doi: 10.1007/s000110050186. Inflamm Res. 1997. PMID: 9266276 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

89 results

Search Page

Filters